Liquidia Technologies Gains Market Shares with YUTREPIA – Revenue Increases by 74% Quarter-over-Quarter!

Liquidia Technologies (LQDA) is successfully transforming from a purely development company into a commercial biopharma player, currently selling YUTREPIA (treprostinil), an approved inhalation powder for the treatment of severe lung diseases. In just 7 months since FDA approval, 2,800 prescriptions have been achieved, while the competing product TYVASO, available for 15 years, currently reaches 10,000 patients. With YUTREPIA, patients can also receive 3 to 4 times more active ingredient in their lungs than with the standard dose of TYVASO. ...